The effects of tetrandrine tablets on inflammatory cytokines and acute phase response following the first-dose of zoledronic acid in postmenopausal osteoporosis patients
10.12206/j.issn.2097-2024.202508039
- VernacularTitle:汉防己甲素片对绝经后骨质疏松症患者首次唑来膦酸治疗后炎性细胞因子及急性期反应的影响
- Author:
Zhanfei XU
1
;
Li LI
1
;
Xiangyang TONG
1
;
Xuechao ZHAO
1
Author Information
1. Department of Emergency, b.Department of Trauma Center, the Affliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou 221000, China.
- Publication Type:Medicine&Clinical
- Keywords:
tetrandrine tablets;
postmenopausal osteoporosis;
zoledronic acid;
acute phase reaction;
inflammatory cytokines
- From:
Journal of Pharmaceutical Practice and Service
2026;44(4):216-220
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of tetrandrine tablets on inflammatory cytokines and acute phase response following the first-dose of zoledronic acid in postmenopausal osteoporosis patients. Methods 80 postmenopausal osteoporosis patients receiving the first-dose of zoledronic acid admitted in the Affliated Xuzhou Municipal Hospital of Xuzhou Medical University from June, 2022 to December, 2024 were selected as study objects, and the patients were randomly divided into control group （40 cases, prophylactic treatment with acetaminophen tablets） and study group （40 cases, prophylactic treatment with tetrandrine tablets and acetaminophen tablets）. The high-sensitivity C-reactive protein （hs-CRP）, interleukin-1β （IL-1β）, IL-6, tumor necrosis factor-α （TNF-α） and the occurrence of acute phase reactions （fever, muscle and joint pain, gastrointestinal discomfort） between two groups were compared. Results The levels of serum hs-CRP, IL-1β, IL-6, and TNF-α in both groups significantly increased on day 1 and day 3 after infusion of zoledronic acid （all P values <0.05）. The levels of serum hs-CRP, IL-6, and TNF-α in the control group were higher than those in the study group on day 1 and 3 after infusion of zoledronic acid, with statistical significance （all P values <0.05）. In terms of acute phase reactions, the incidence of fever, muscle and joint pain in the control group after infusion of zoledronic acid were higher than those in the study group, with statistical significance （P<0.05）. No statistically significant difference in the incidence of gastrointestinal discomfort between the two groups （P>0.05）. Conclusion Tetrandrine tablets could reduce the expression levels of hs-CRP, IL-1β, IL-6, and TNF-α following the first-dose of zoledronic acid in postmenopausal osteoporosis patients, reduce the incidence of acute phase reactions, and alleviate adverse reactions.
